| 摘要 |
To provide a remedy or ameliorant, based on the effect of inducing cell differentiation, for diseases such as hematopoietic organ tumors and solid tumors for which no clinically highly useful drug has been known hitherto. The fundamental idea of the conventional pharmacotherapy for cancer resides in completely exterminating tumor cells having an unusually high capability of multiplication. However these treatments also had toxicities against normal cells and thus grave side effects were unavoidable. Further, only limited therapeutic effects could be achieved. On the other hand, although all-trans-retinoic acid had a remarkable effect on acute promyelocytic leukemia, there was reported that this compound also had grave side effects. Further, there was another problem that the diseases tended to recur after it was healed. In contrast, (2E,4E,6E,10E)3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid has an unexpected effect of inducing cell differentiation and a high safety. Being different in structure from all-trans-retinoic acid, this compound has a high possibility of preventing the recurrence of the disease. Therefore, it is expected as a clinically useful remedy or ameliorant for hematopoietic organ tumors, in particular, acute promyelocytic leukemia and myeloid dysplasia syndrome.
|
